Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 2.03 (Creation of a Direct Financial Obligation), Item 5.02 (Departure/Election of Directors or Officers), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $650M senior secured term loan fully drawn November 2, 2026 to fund the merger, refinance debt, transaction costs and corporate purposes.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $650M senior secured term loan fully drawn November 2, 2026 to fund the merger, refinance debt, transaction costs and corporate purposes
- Initial pricing: Term SOFR plus 2.25% or Base Rate plus 1.25%, at company election
- Post-reporting pricing: Term SOFR spread 2.00%-2.75%, or Base Rate spread 1.00%-1.75%, tied to total net leverage
- First-priority liens on substantially all borrower collateral, with subsidiary guarantees across the U.S. and U.K.
- Leverage and interest-coverage covenants restrict additional debt, investments, distributions and acquisitions, increasing refinancing and default risk
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Indivior completed its merger with Supernus, creating a combined company with former Supernus holders receiving Indivior equity
- Exchange ratio: 1.5401 Indivior shares per Supernus share, with cash paid for fractional shares
- Ownership split: legacy Indivior stockholders 56.5%, former Supernus stockholders 43.5% fully diluted
- Supernus equity awards converted into Indivior awards, while performance-based awards became time-based vesting
- Transaction expands Indivior’s fully diluted share base and introduces potential future dilution from rollover options and awards
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a newly created direct financial obligation tied to a material agreement
- Investor impact depends on the borrowing amount, pricing, maturity and repayment terms disclosed under Item 1.01
Item 5.02 · Departure/Election of Directors or Officers
- Merger-driven leadership reset: Indivior’s CEO, CFO, commercial chief and legal chief departed at closing
- CEO Joseph Ciaffoni separation payments total $3,345,000, plus 18 months of health benefits and full RSU vesting
- CFO Ryan Preblick separation payments total $1,207,050, plus 15 months of benefits and accelerated equity awards
- Supernus CEO Jack Khattar became Combined Company CEO, with $1,115,000 salary and 100% target bonus
- Board shifted to eight directors, evenly split between four Indivior and four Supernus designees, with Tony Kingsley as chair
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Corporate name changed from Indivior Pharmaceuticals, Inc. to Supernus, Inc. upon merger completion
- Nasdaq ticker changing from INDV to SUPN around November 3, 2026
- Shareholders must use SUPN for post-merger trading and market data identification
Item 7.01 · Regulation FD Disclosure
- Indivior announced completion of the merger, marking the transaction’s closing and transition to combined-company operations
- Merger completion may affect ownership, capital structure, reporting, and strategic priorities going forward
- Exhibit 99.1 contains the press release with transaction-specific details for investor review
Item EX-99.1 · Exhibit EX-99.1
- Merger closed, creating Supernus, Inc., an 11-product CNS platform spanning opioid use disorder, psychiatry, and neurology
- Indivior shareholders receive a $1.0 billion aggregate special dividend, funded partly by a $650 million Citibank term loan
- Former Indivior shareholders own approximately 56.5% of the combined company, versus 43.5% for former Supernus shareholders
- Combined company begins Nasdaq Global Market trading under SUPN on November 3, 2026, after Indivior trading on November 2
- Jack Khattar becomes CEO and Tony Kingsley Board Chair, with an eight-member board split evenly between legacy companies
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.